News & Updates

Telitacicept shows promise in systemic lupus erythematosus

30 Dec 2023

Telitacicept, a novel fusion protein that neutralizes signals of B lymphocyte stimulator and a proliferation-inducing ligand, is safe and helps improve the symptoms of systemic lupus erythematosus, as shown in a phase IIb study.

Telitacicept shows promise in systemic lupus erythematosus

30 Dec 2023

Brolucizumab noninferior to aflibercept for diabetic macular edema

29 Dec 2023

In the treatment of individuals with diabetic macular edema, brolucizumab yields similar visual outcomes as aflibercept, according to data from the phase III KINGFISHER trial.

Brolucizumab noninferior to aflibercept for diabetic macular edema

29 Dec 2023

$Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma$

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

29 Dec 2023 by

In the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), taking ibrutinib and venetoclax together prolongs survival without disease progression, according to the phase III Sympatico study.

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

29 Dec 2023

What are the predictors of disability in pancreatitis patients?

29 Dec 2023

Several factors characterize and even predict disability in patients with chronic pancreatitis (CP), suggests a study. These predictors can be targeted to reduce disease burden and healthcare expenditure.

What are the predictors of disability in pancreatitis patients?

29 Dec 2023

Severe outcomes more likely with Omicron XBB.1.16 in SG

29 Dec 2023 by

In a preliminary analysis, the risk of severe outcomes was higher in individuals infected with the Omicron XBB.1.16 subvariant compared with those who were infected with other subvariants such as the XBB.1.5 or XBB.1.9.

Severe outcomes more likely with Omicron XBB.1.16 in SG

29 Dec 2023

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

The oral selective tyrosine kinase inhibitor sunvozertinib demonstrates therapeutic potential in patients with nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertions (exon20ins) who have previously received platinum-based chemotherapy, according to the results of a phase II WU-KONG6 study.

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

Novel probiotics may improve mood disorder symptoms and sleep quality

29 Dec 2023 by

A novel multi-strain E3 probiotic formulation improves symptoms of depression and anxiety as well as sleep quality, a prospective cohort study has shown.

Novel probiotics may improve mood disorder symptoms and sleep quality

29 Dec 2023

Upadacitinib induces CD remission in patients with prior surgery

28 Dec 2023 by

Treatment with upadacitinib (UPA) delivers clinical benefits to patients with prior Crohn’s disease (CD)-related surgeries, according to a study presented at AIBD 2023. Moreover, a maintenance dose of 30 mg once a day (QD) demonstrates greater efficacy.

Upadacitinib induces CD remission in patients with prior surgery

28 Dec 2023

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023 by

The novel, investigational anti-tissue factor pathway inhibitor marstacimab outdid factor replacement therapy (FRT) in reducing bleeds in patients with severe haemophilia A (HA) or moderately severe to severe haemophilia B (HB) without inhibitors beyond 12 months in the phase III BASIS trial.

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023

Risankizumab superior to ustekinumab in severe CD

27 Dec 2023 by

Risankizumab outdoes ustekinumab in achieving endoscopic remission at week 24 in patients with moderate-to-severe Crohn’s disease (CD), as well as in other clinical, endoscopic, and quality of life (QoL) outcomes, as shown by the results of the phase IIIB SEQUENCE trial presented at AIBD 2023.

Risankizumab superior to ustekinumab in severe CD

27 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

Telitacicept shows promise in systemic lupus erythematosus

Telitacicept shows promise in systemic lupus erythematosus

Brolucizumab noninferior to aflibercept for diabetic macular edema

Brolucizumab noninferior to aflibercept for diabetic macular edema

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

What are the predictors of disability in pancreatitis patients?

What are the predictors of disability in pancreatitis patients?

Severe outcomes more likely with Omicron XBB.1.16 in SG

Severe outcomes more likely with Omicron XBB.1.16 in SG

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

Novel probiotics may improve mood disorder symptoms and sleep quality

Novel probiotics may improve mood disorder symptoms and sleep quality

Upadacitinib induces CD remission in patients with prior surgery

Upadacitinib induces CD remission in patients with prior surgery

Marstacimab trumps FRT for severe haemophilia without inhibitors

Marstacimab trumps FRT for severe haemophilia without inhibitors

Risankizumab superior to ustekinumab in severe CD

Risankizumab superior to ustekinumab in severe CD